Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL OTCMKTS:NWBO NASDAQ:SDGR NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$35.23-1.6%$34.69$29.19▼$50.79$1.16B0.73434,726 shs286,216 shsNWBONorthwest Biotherapeutics$0.18+0.1%$0.21$0.18▼$0.37$299.01M-0.632.87 million shs2.80 million shsSDGRSchrodinger$16.49-1.8%$14.57$10.94▼$23.75$1.24B1.621.35 million shs1.10 million shsWVEWAVE Life Sciences$6.25-1.0%$6.27$5.02▼$21.73$1.21B-1.292.97 million shs3.54 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-1.62%-4.86%+1.24%-0.68%+8.87%NWBONorthwest Biotherapeutics+0.06%-3.89%-6.86%-11.00%-24.51%SDGRSchrodinger-1.79%-2.31%+16.54%+45.03%-23.94%WVEWAVE Life Sciences-0.95%-0.16%+10.42%-12.95%-18.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$35.23-1.6%$34.69$29.19▼$50.79$1.16B0.73434,726 shs286,216 shsNWBONorthwest Biotherapeutics$0.18+0.1%$0.21$0.18▼$0.37$299.01M-0.632.87 million shs2.80 million shsSDGRSchrodinger$16.49-1.8%$14.57$10.94▼$23.75$1.24B1.621.35 million shs1.10 million shsWVEWAVE Life Sciences$6.25-1.0%$6.27$5.02▼$21.73$1.21B-1.292.97 million shs3.54 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-1.62%-4.86%+1.24%-0.68%+8.87%NWBONorthwest Biotherapeutics+0.06%-3.89%-6.86%-11.00%-24.51%SDGRSchrodinger-1.79%-2.31%+16.54%+45.03%-23.94%WVEWAVE Life Sciences-0.95%-0.16%+10.42%-12.95%-18.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 3.17Buy$57.5063.21% UpsideNWBONorthwest Biotherapeutics 0.00N/AN/AN/ASDGRSchrodinger 2.33Hold$20.2522.80% UpsideWVEWAVE Life Sciences 2.87Moderate Buy$26.41322.59% UpsideCurrent Analyst Ratings BreakdownLatest NWBO, SDGR, WVE, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026COLLCollegium Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/29/2026COLLCollegium Pharmaceutical Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/15/2026COLLCollegium Pharmaceutical Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/11/2026WVEWAVE Life Sciences New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.006/11/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026WVEWAVE Life Sciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$13.00 ➝ $14.005/19/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $13.005/14/2026SDGRSchrodinger Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$19.00 ➝ $17.005/4/2026WVEWAVE Life Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $24.004/30/2026WVEWAVE Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.004/29/2026WVEWAVE Life Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00 ➝ $15.00(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$780.57M1.46$14.99 per share2.35$9.54 per share3.69NWBONorthwest Biotherapeutics$1.38M216.80N/AN/A($0.04) per share-4.45SDGRSchrodinger$255.87M4.76N/AN/A$4.94 per share3.34WVEWAVE Life Sciences$42.73M28.14N/AN/A$3.10 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$62.87M$2.0417.275.96N/A9.41%95.18%16.39%8/6/2026 (Estimated)NWBONorthwest Biotherapeutics-$60.16M-$18.23N/AN/AN/A-2,931.73%N/A-79.26%8/13/2026 (Estimated)SDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%8/5/2026 (Estimated)WVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%7/30/2026 (Estimated)Latest NWBO, SDGR, WVE, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026COLLCollegium Pharmaceutical$1.68N/AN/AN/A$199.48 millionN/A8/5/2026Q2 2026SDGRSchrodinger-$0.60N/AN/AN/A$47.45 millionN/A7/30/2026Q2 2026WVEWAVE Life Sciences-$0.31N/AN/AN/A$7.45 millionN/A5/7/2026Q1 2026COLLCollegium Pharmaceutical$1.52$1.76+$0.24$0.40$184.47 million$193.52 million5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical2.471.711.62NWBONorthwest BiotherapeuticsN/A0.070.07SDGRSchrodingerN/A2.742.74WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/ANWBONorthwest Biotherapeutics0.04%SDGRSchrodinger79.05%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical1.85%NWBONorthwest Biotherapeutics2.40%SDGRSchrodinger10.10%WVEWAVE Life Sciences24.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.43 million31.83 millionOptionableNWBONorthwest Biotherapeutics201.68 billion1.64 billionNot OptionableSDGRSchrodinger79073.82 million66.37 millionOptionableWVEWAVE Life Sciences240192.40 million145.65 millionOptionableNWBO, SDGR, WVE, and COLL HeadlinesRecent News About These CompaniesWAVE Life Sciences (NASDAQ:WVE) Trading Down 8.3% - What's Next?July 10 at 12:39 PM | marketbeat.comWave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for RedomiciliationJuly 7, 2026 | globenewswire.comDoes Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?July 1, 2026 | zacks.comWave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM TrialJune 30, 2026 | insidermonkey.comWave Life Sciences Shareholders Approve Redomiciliation SchemeJune 26, 2026 | tipranks.comWave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic DiseasesJune 24, 2026 | globenewswire.comWave Life Sciences (WVE) Upgraded to Buy: Here's WhyJune 16, 2026 | zacks.comIs Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?June 13, 2026 | insidermonkey.comMizuho Securities Remains a Buy on Wave Life Sciences (WVE)June 13, 2026 | theglobeandmail.comIs Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?June 13, 2026 | finance.yahoo.comBillionaire Lee Ainslie’s 5 Stocks with Huge Upside PotentialJune 12, 2026 | insidermonkey.comInside Wells Fargo’s Take on Wave Life Sciences Ltd (WVE) StockJune 12, 2026 | insidermonkey.comWave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comWave Life Sciences to Present at Upcoming Investor ConferencesJune 1, 2026 | globenewswire.comThis $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First QuarterMay 31, 2026 | fool.comAnalysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Boston Scientific (BSX)May 29, 2026 | theglobeandmail.comWave Life Sciences Ltd. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their LossesMay 27, 2026 | globenewswire.comShould WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors?May 25, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Gossamer Bio (GOSS) and Cullinan Management (CGEM)May 21, 2026 | theglobeandmail.comWave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD DataMay 20, 2026 | seekingalpha.comWVE stock edges up after positive early data for rare disease drugMay 20, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWBO, SDGR, WVE, and COLL Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$35.23 -0.58 (-1.62%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$35.22 -0.01 (-0.03%) As of 07/10/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Northwest Biotherapeutics OTCMKTS:NWBO$0.18 +0.00 (+0.06%) As of 07/10/2026 03:59 PM EasternNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Schrodinger NASDAQ:SDGR$16.49 -0.30 (-1.79%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$16.43 -0.06 (-0.38%) As of 07/10/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.WAVE Life Sciences NASDAQ:WVE$6.25 -0.06 (-0.95%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$6.17 -0.08 (-1.28%) As of 07/10/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
